Zhejiang Orient Gene Biotech Co Ltd (688298) — Capital Reinvestment Ratio
Latest as of September 2022:
0.39x
Zhejiang Orient Gene Biotech Co Ltd (688298) has a Capital Reinvestment Ratio of 0.39x as of September 2022, meaning it reinvests 0% of its operating cash flow (CN¥309.89 Million) in capital expenditures (CN¥119.58 Million). See 688298 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.39x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥309.89 Million
CNY
Capital Expenditures
CN¥119.58 Million
CNY
Data as of
Sep 2022
Most recent filing
Zhejiang Orient Gene Biotech Co Ltd Capital Reinvestment Ratio (2016–2022)
This chart tracks Zhejiang Orient Gene Biotech Co Ltd's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Zhejiang Orient Gene Biotech Co Ltd (2016–2022)
Year-by-year Capital Reinvestment Ratio for Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2022. For live market cap and broader valuation context, see 688298 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.35x | CN¥3.00 Billion | CN¥1.05 Billion | ▲ +259.8% |
| 2021 | 0.10x | CN¥5.20 Billion | CN¥507.87 Million | ▲ +37.7% |
| 2020 | 0.07x | CN¥1.79 Billion | CN¥126.93 Million | ▼ -67.7% |
| 2019 | 0.22x | CN¥54.21 Million | CN¥11.90 Million | ▼ -48.5% |
| 2018 | 0.43x | CN¥44.33 Million | CN¥18.88 Million | ▲ +6.7% |
| 2017 | 0.40x | CN¥33.54 Million | CN¥13.38 Million | ▲ +1.3% |
| 2016 | 0.39x | CN¥11.81 Million | CN¥4.65 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow